HMGB1 and diabetes mellitus: GA, an inhibitor of HMGB1, reduces endothelium-dependent relaxation impairment by upregulating eNOS expression in an animal model of diabetes (Zhu et al., 2020a; Zhou et al., 2021), and it attenuates neointimal formation in a rat model of iliac artery balloon injury (Zhu et al., 2020b).